Autoimmunity
Autoimmunity(自身免疫)
Autoimmunity 相关产品(179)
- GC426449-DeazaguanineCAS: 65996-58-9纯度: >98.00%
9-Deazaguanine是一种嘌呤核苷类似物，具有口服活性，作为嘌呤核苷磷酸化酶(PNP)的强效抑制剂。
- GC42691Aceclofenac ethyl esterCAS: 139272-67-6纯度: >98.00%
A potential impurity found in commercial preparations of aceclofenac
- GC42692Aceclofenac methyl esterCAS: 139272-66-5纯度: >98.00%
A potential impurity in commercial preparations of aceclofenac
- GC42953BMS 345541 (trifluoroacetate salt)纯度: >98.00%
BMS 345541 is a cell permeable inhibitor of the IκB kinases IKKα and IKKβ (IC50s = 4 and 0.3 μM).
- GC43444Diclofenac Acyl-β-D-GlucuronideCAS: 64118-81-6纯度: >95.00%
An active metabolite of diclofenac
- GC43494DL-threo-PDMP (hydrochloride)CAS: 80938-69-8纯度: >98.00%
An inhibitor of sphingolipid biosynthesis
- GC43804Halofuginone (hydrochloride)CAS: 1217623-74-9纯度: >95.00%
An inhibitor of TGF-β signaling and T H 17 differentiation
- GC43833Histone H3 (23-34) (human, mouse, rat, bovine) (trifluoroacetate salt)纯度: >95.00%
A peptide fragment of histone H3
- GC44257Myelin Basic Protein (87-99) (human, bovine, rat) (trifluoroacetate salt)纯度: >95.00%
An encephalitogenic peptide
- GC44388NF-κB ControlCAS: 201608-17-5纯度: >95.00%
A negative control peptide used with NF-κB inhibitor
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC42608 | 7-hydroxy Methotrexate (sodium salt) | - | >96.00% | |
A metabolite of methotrexate | ||||
| GC42644 | 9-Deazaguanine | 65996-58-9 | >98.00% | |
9-Deazaguanine是一种嘌呤核苷类似物，具有口服活性，作为嘌呤核苷磷酸化酶(PNP)的强效抑制剂。 | ||||
| GC42691 | Aceclofenac ethyl ester | 139272-67-6 | >98.00% | |
A potential impurity found in commercial preparations of aceclofenac | ||||
| GC42692 | Aceclofenac methyl ester | 139272-66-5 | >98.00% | |
A potential impurity in commercial preparations of aceclofenac | ||||
| GC42856 | AS-605240 (potassium salt) | - | >98.00% | |
A potent inhibitor of PI3Kγ | ||||
| GC42877 | AUY954 | 820240-77-5 | >98.00% | |
A selective S1P 1 receptor agonist | ||||
| GC42880 | Avenanthramide-C methyl ester | 955382-52-2 | >90.00% | |
Inhibitor of NF-κB activation | ||||
| GC42953 | BMS 345541 (trifluoroacetate salt) | - | >98.00% | |
BMS 345541 is a cell permeable inhibitor of the IκB kinases IKKα and IKKβ (IC50s = 4 and 0.3 μM). | ||||
| GC43007 | C12 Galactosylceramide (d18:1/12:0) | 41613-14-3 | >98.00% | |
A bioactive sphingolipid | ||||
| GC43076 | C24 Phytosphingosine (t18:0/24:0) | 34437-74-6 | >98.00% | |
A sphingolipid | ||||
| GC43077 | C24:1 3'-sulfo Galactosylceramide (d18:1/24:1(15Z)) | 151057-28-2 | >98.00% | |
A sulfatide | ||||
| GC43176 | CAY10575 | 916985-21-2 | >95.00% | |
An IKKβ and Plk1 inhibitor | ||||
| GC43340 | Cyclic di-IMP (sodium salt) | - | >95.00% | |
A synthetic second messenger | ||||
| GC43444 | Diclofenac Acyl-β-D-Glucuronide | 64118-81-6 | >95.00% | |
An active metabolite of diclofenac | ||||
| GC43447 | Diclofenac methyl ester | 15307-78-5 | >98.00% | |
A prodrug form of diclofenac | ||||
| GC43494 | DL-threo-PDMP (hydrochloride) | 80938-69-8 | >98.00% | |
An inhibitor of sphingolipid biosynthesis | ||||
| GC43804 | Halofuginone (hydrochloride) | 1217623-74-9 | >95.00% | |
An inhibitor of TGF-β signaling and T H 17 differentiation | ||||
| GC43833 | Histone H3 (23-34) (human, mouse, rat, bovine) (trifluoroacetate salt) | - | >95.00% | |
A peptide fragment of histone H3 | ||||
| GC43848 | Histone H3K27Me2 (23-34) (trifluoroacetate salt) | - | >95.00% | |
A peptide fragment of histone H3 | ||||
| GC43894 | IKK2 Inhibitor VI | 354811-10-2 | >95.00% | |
An inhibitor of IKK2 | ||||
| GC44078 | LL-37 amide (trifluoroacetate salt) | - | >95.00% | |
An antimicrobial peptide | ||||
| GC44257 | Myelin Basic Protein (87-99) (human, bovine, rat) (trifluoroacetate salt) | - | >95.00% | |
An encephalitogenic peptide | ||||
| GC44388 | NF-κB Control | 201608-17-5 | >95.00% | |
A negative control peptide used with NF-κB inhibitor | ||||
| GC44505 | Oleyl Anilide | 5429-85-6 | >95.00% | |
An ACAT inhibitor | ||||